NAMPT and neoplasm: In an attempt to leverage increased tumor-cell reliance on NAD+ synthesis, small molecule inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) were developed (e.g., FK866).4 NAMPT catalyzes the rate-limiting step of the most active pathway of NAD+ synthesis.